This, along with the observation that the soluble ACE2 ectodomain specifically blocked infection by SARS-CoV S-bearing pseudotypes, shows that the use of soluble recombinant ACE2 may be helpful in reducing lung injury in COVID-19. Here, ACE2 is linked to COVID-19.